This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-14. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Carboxylation of these vitamin K-dependent Gla-proteins, besides being essential for the function of the protein, is also an important vitamin recovery mechanism since it serves as a recycling pathway to recover vitamin K from its epoxide metabolite (KO) for reuse in carboxylation. Several human Gla-containing proteins synthesized in several different types of tissue have been discovered:
Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS (1987). "An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes". J. Biol. Chem. 262 (18): 8532–6. doi:10.1016/S0021-9258(18)47446-7. PMID 3597387. Fischer WH, Spiess J (1987). "Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides". Proc. Natl. Acad. Sci. U.S.A. 84 (11): 3628–32. Bibcode:1987PNAS...84.3628F. doi:10.1073/pnas.84.11.3628. PMC 304928. PMID 3473473. Messer M; Ottesen M (1965). "Isolation and properties of glutamine cyclotransferase of dried papaya latex". C. R. Trav. Lab. Carlsberg. 35 (1): 1–24. PMID 5846578.
A number of sweet carbonated beverages can be produced by the same methods as beer, except the fermentation is stopped sooner, producing carbon dioxide, but only trace amounts of alcohol, leaving a significant amount of residual sugar in the drink.
Sources: en.wikipedia.org
=== Effects of early and late puberty onset === Several studies about puberty have examined the effects of an early or a late onset of puberty in males and females. In general, females who enter puberty late experience positive outcomes in adolescence and adulthood, while females who enter puberty early experience negative outcomes. Males who have earlier pubertal timing generally have more positive outcomes in adulthood but more negative outcomes in adolescence, while the reverse is true for later pubertal timing.
=== Electrical === In electrical FFF a transverse electrical current (DC) is applied which creates an electric field. Depending on the charge of sample components, an electrophoretic drift velocity is induced, counteracted by the diffusion from Brownian motion, so the separation depends on the ratio of electrophoretic mobility and size. Application of electrical FFF has been limited and is currently rarely used. Other modifications have been developed, namely cyclical electrical FFF where a special alternating current is applied. It allows to separate according to electrophoretic mobility. Another variation is electrical asymmetrical flow FFF (EAF4), where an electrical field is applied in addition to a cross flow field. EAF4 overcomes the limitation of pure electrical FFF which has poor resolution and suffers from electrolysis products and bubbles contaminating the channel outflow and compromising the detector signals.
=== Analysis === At one time, coordination compounds were used to identify the presence of metals in a sample. Qualitative inorganic analysis has largely been superseded by instrumental methods of analysis such as atomic absorption spectroscopy (AAS), inductively coupled plasma atomic emission spectroscopy (ICP-AES) and inductively coupled plasma mass spectrometry (ICP-MS).
== Applications == Enzyme inhibitors are found in nature and also produced artificially in the laboratory. Naturally occurring enzyme inhibitors regulate many metabolic processes and are essential for life. In addition, naturally produced poisons are often enzyme inhibitors that have evolved for use as toxic agents against predators, prey, and competing organisms. These natural toxins include some of the most poisonous substances known. Artificial inhibitors are often used as drugs, but can also be insecticides such as malathion, herbicides such as glyphosate, or disinfectants such as triclosan. Other artificial enzyme inhibitors block acetylcholinesterase, an enzyme which breaks down acetylcholine, and are used as nerve agents in chemical warfare.
Sources: en.wikipedia.org
== History == The PUN was founded in 1957 as a political platform to support the presidential candidacy of "Papa Doc" Duvalier in the 1957 general election. In the aftermath of the July 1958 coup attempt, the Tonton Macoute — officially named Volunteers of the National Security (French: Volontaires de la Sécurité Nationale, VSN) — was formed as the paramilitary wing of the PUN. In 1963, other political parties in Haiti were outlawed, making the PUN the single political party of the nation. When "Papa Doc" Duvalier died in 1971, his son "Baby Doc" Duvalier succeeded him as the President of the country and the leader of the party. The party would remain in power until the fall and exile of "Baby Doc" Duvalier in 1986, at the height of the Anti-Duvalier protest movement, after which the party would enter a low profile stage, including the change of its name to National Progressive Party (French: Parti progressiste national, PPN). After the return of "Baby Doc" Duvalier from exile in 2011, the party began a process of reconstitution under its original name from 2014, and started opening departmental offices. Suffering a setback with the death of "Baby Doc" Duvalier in 2014, the party nominated Marc-Arthur Drouillard as its candidate in the 2015 presidential election. Towards that time, the legal representative of the party was Philomène Exe.
Studies on deep sea shrimp have shown the potential for flood lights used on the sea floor used in studying the vent systems to cause permanent retinal damage, warranting further research into the potential risk to other vent organisms. On top of the risk presented to deep-sea organisms, the surface support vessels use nocturnal anthropogenic lighting. Research has shown that this type of lighting on the ocean surface can disorient seabirds and cause fallout, where they fly toward the anthropogenic light and become exhausted or collide with man-made objects, resulting in injury or death. There is consideration for both aquatic and land organisms when evaluating the environmental effects of hydrothermal vent mining. There are three mining waste processes, known as the side cast sediment release, dewatering process, and sediment shift or disturbance, that would be expected with the deep-sea mining processes and could result in the accumulation of a sediment plume or cloud, which can have substantial environmental implications. The side cast sediment release is a process that would occur at the seafloor and would involve the move of material at the seafloor by the submerged ROV's and would most likely contribute to the formation of sediment plumes at the seafloor. The idea of side cast release is that the ROV's would discard economically invaluable material to the side of the mining sight before transporting the sulfide material to the supporting vessel at the surface.
== Function == The adiponectin receptors, AdipoR1 and AdipoR2, serve as receptors for globular and full-length adiponectin and mediate increased AMPK and PPAR-α ligand activities, as well as fatty acid oxidation and glucose uptake by adiponectin. In 2016, the University of Tokyo announced that it would launch an investigation into claims of fabrication of AdipoR1 and AdipoR2 identification data, as accused by an anonymous person/group called Ordinary researchers.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.